On the other hand, activation of PPARα and mitochondrial β‐oxidation ameliorates liver steatosis in preclinical models (Li et al., 2014; Pawlak, Lefebvre, & Staels, 2015), indicating a new potential therapeutic area. This evidence concerns the gene PPARA and fatty liver disease.